Nuvectis Pharma (Nuvectis Pharma) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Nuvectis Pharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Nuvectis Pharma's Free Cash Flow for the three months ended in Dec. 2023 was $-3.85 Mil. Nuvectis Pharma's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Nuvectis Pharma's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Nuvectis Pharma's current FCF Yield % is -10.67%.

The historical rank and industry rank for Nuvectis Pharma's FCF Margin % or its related term are showing as below:

NVCT's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -147.18
* Ranked among companies with meaningful FCF Margin % only.

Nuvectis Pharma FCF Margin % Historical Data

The historical data trend for Nuvectis Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvectis Pharma FCF Margin % Chart

Nuvectis Pharma Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Nuvectis Pharma Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of Nuvectis Pharma's FCF Margin %

For the Biotechnology subindustry, Nuvectis Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuvectis Pharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvectis Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Nuvectis Pharma's FCF Margin % falls into.

Nuvectis Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Nuvectis Pharma's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-15.954	/	0
	=	%

Nuvectis Pharma's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-3.85	/	0
	=	%

Nuvectis Pharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Nuvectis Pharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvectis Pharma (Nuvectis Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvectis Pharma Inc (NAS:NVCT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, NJ, USA, 07024

Website

https://www.nuvectis.com

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. Its pipeline products include NXP800, NXP900.

Executives

Ron Bentsur	director, officer: Chairman & CEO	750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Marlio Charles Mosseri	10 percent owner	27 RIPPLEVALE GROVE, LONDON X0 N1 1HS
Enrique Poradosu	officer: Chief Science and Business Off	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, FORT LEE NJ 07024
Shay Shemesh	officer: Chief Development Officer	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Michael J. Carson	officer: Vice President, Finance	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024
Kenneth Hoberman	director	750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10024
Oliviero James F Iii	director	C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Uri Ben-or	officer: Int. Principal Financial Off.	C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Matthew L. Kaplan	director	C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE NJ 07024